Navigation Links
Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statistical significance, and also showed trends towards improvement in pain-free status and improvement of migraine pain at other time points. ADX10059 has already recently demonstrated a potential therapeutic benefit in a Phase IIa study in gastro-esophageal reflux disease (GERD), and is currently completing a Phase IIa study in anxiety.

ADX10059 is a potent, selective, negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5 NAM). Various pre-clinical pharmacology experiments have shown that glutamate is largely responsible for signal transmission in the neural circuit involved in migraine, and mGluR5 receptors are found at strategic points along the pathway. Inhibition of mGluR5 might therefore prevent the initiation of the migraine circuit, or interrupt it once established. For this initial exploratory study on the utility of an mGluR5 NAM in the management of migraine, an acute treatment paradigm was used.

The study was conducted in 129 migraine patients at opinion leader sites in the UK and Germany, according to the gold-standard design used for acute treatment of migraine. It comprised a multi-centre, double-blind, placebo-controlled comparison of a single dose of ADX10059 with placebo, to treat a single moderate or severe (IHS Grade 2 or 3) migraine headache, in an outpatient setting. Standard efficacy outcomes were used, with the primary efficacy variable being the proportion of patients pain-free (IHS Grade 0) 2 hours after dosing.

ADX10059 met the primary endpoint, showing a statistically significant higher number of patients pain-free 2 hours after dosing compared to placeb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:5/23/2013)... May 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of novel bile ... primary biliary cirrhosis, today announced that Mark ... will present at the Deutsche Bank Securities 38th Annual ... on Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)... 23, 2013  Inhibikase Therapeutics, Inc., an emerging ... it will present new results on its antiviral ... sponsored by the PML Consortium (composed of Pfizer, ... (JCV) is the causative agent of Progressive Multifocal ... in an extended release formulation, can clear JC ...
(Date:5/23/2013)... -- PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in New York.  James Winschel, ... will be making a presentation on PAREXEL and discussing ... 2013. A live webcast of the presentation ... website at www.PAREXEL.com in the Upcoming Events ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2PAREXEL International To Present At Jefferies Healthcare Conference 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:5/23/2013)... characterized as "triple negative" carries a poor prognosis, with ... kill the cancer cells the way it,s supposed to. ... cells don,t respond to chemotherapy, and identifies a mechanism ... Dr. Shawn Li, PhD, and his team at Western,s ... protein called Numb functions to promote the death of ...
(Date:5/23/2013)... Former United States Vice President Dick Cheney served ... Paramedic Luncheon. , In front of 1,500 guests ... medics, saying, "I am delighted to be here to ... of the Year Award. I think it's a tremendous ... within a company like this because there are obviously ...
(Date:5/23/2013)... May 23, 2013 On April 29th, 2013, ... midst of growing numbers of H7N9 cases and deaths. The ... Bird Flu Cases Will Subside in Northern Hemisphere as Available ... new cases have been reported. , Quoting Kevin McGuire, ... as predictable as flowers budding in the spring and leaves ...
(Date:5/23/2013)... EnvirOasis, the leader in energy efficient ... is pleased to announce its new line of Energy ... EnvirOasis has been a market leader in Fluorescent ... and has recently brought to market a full line ... is energy efficient lighting technology which produces a very ...
(Date:5/23/2013)... Doheny HealthDay Reporter , , THURSDAY, May 23 (HealthDay ... dropping sharply, especially among Hispanic teens, according to a new ... aged 15 to 19 dropped by nearly one half from ... 1,000 teens to 31 births for every 1,000. From ... fell 25 percent, from 41.5 to about 31. During ...
Breaking Medicine News(10 mins):Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3
... Spanish psychologists and a German neurologist have recently shown that ... noun is different from the part used when a verb ... using functional magnetic resonance, according to an article they have ... "Learning nouns activates the left fusiform gyrus, while learning verbs ...
... not helped patients, says AMA president , THURSDAY, Feb. 25 ... vanishing, according to an American Medical Association report that looked ... In 24 of the states, the two largest insurers had ... year, 18 of 42 states had that type of market ...
... ... ... Advans, a solution provider and IT consulting firm, has announced today, the results of ... IT Outsourcing Survey, 75 percent of executives prefer outsourcing domestically rather than offshore. ...
... ... Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a new ... OA progression. , ... Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for Sports ...
... ... Distributors continue to await their orders of Xyngular Xyng™ as Zija,s ... beat Xyngular™ to market months before their NEW! Xyng™ product was ... since. People from all over the world are calling to become ...
... ... clean hands and defense against colds and H1N1 flu virus as near as your closest ... to prevent infection and illness. Now teachers in classrooms anywhere can encourage frequent hot-water hand-washing ... ...
Cached Medicine News:Health News:Nouns and verbs are learned in different parts of the brain 2Health News:Nouns and verbs are learned in different parts of the brain 3Health News:Health Insurance Competition Vanishing: Study 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3Health News:Angeles Launches New Portable Hot Water Sinks 2Health News:Angeles Launches New Portable Hot Water Sinks 3Health News:Angeles Launches New Portable Hot Water Sinks 4
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
This 500 tip allows you to draw the full volume of compatible Biohit and Eppendorf pipettors....
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
MBP's 200 ul large orifice tip is perfect for handling fragile cells, viscous samples, and genomic DNA....
Medicine Products: